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on right arch of foot before first platelet-rich plasma
therapy.L
ivedoid vasculopathy is a chronic disorder
diagnosed based on clinical features such as
cutaneous ulcers, atrophic, stellate scars with
peripheral telangiectasis and hyperpigmentation.1
Platelet-rich plasma (PRP) therapy has been success-
fully used in the treatment of various dermatologic
conditions including pressure ulcers, diabetic ulcers,
and posttraumatic ulcers. The most common PRP
therapy is to obtain a sample of blood directly from
the patient (autologous).2,3
CASE REPORT
A 50-year-old Japanese woman presented with a
20-year history of painful, hyperpigmented, hard,
contracted skin with recalcitrant cutaneous ulcers on
her lower extremities. Shewaspreviously treatedwith
systemic conventional therapies suchas prednisolone
andwarfarin. However, the skin lesions progressed to
painful ulcers with eschars and granulation tissue
during the last 6months (Fig 1). Her lower extremities
exhibited vascular engorgement in a livedoid pattern
over her legs. A biopsy showed dermal fibrosis,
intravascular hyalinized material of fibrin-containing
thrombi with cell inflammation, and capillary dilata-
tion in the papillary to middle dermis consistent with
the clinical diagnosis of livedoid vasculopathy (Fig 2).
Bacterial culture and Gram stain were negative.
We obtained 60 mL of peripheral autologous blood,
collected into tubes containing acid-citrate-dextrose
solution formula anticoagulant. The citrated blood
was centrifuged at room temperature for 15 minutes
at 1100 rpm. After the plasma layer containing the
platelets was collected, the obtained platelet plasmathe Department of Dermatologya and Department of Plastic
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supernatant (called ‘‘platelet-poor plasma’’) was
removed from the platelet sedimentation after centri-
fugation, and then the PRP was adjusted at 10-fold
concentrations by using 6 mL of platelet-poor
plasma. After completion of 3 cycles of autologous
PRP treatments at monthly intervals, the lesion
showed improvement with atrophic scars and min-
imal pain (Fig 3). During the PRP therapy, the patient
received nonsteroidal anti-inflammatory drug.
DISCUSSION
Pathogenesis of livedoid vasculopathy remains
unclear and classification is difficult as a result of
variable nomenclature and the multifactorial nature
of the disease. Idiopathic forms, association with
immune complex, and dermal blood vessel occlu-
sion have been described.4 There is, however,JAAD Case Reports 2015;1:310-1.
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Fig 3. Skin ulcers improved after platelet-rich plasma
therapy.
Fig 2. Skin biopsy specimen of the lower leg revealed
microvascular thrombi within the vessel wall, erythrocyte
extravasation, and inflammatory cell infiltration in the
papillary and mid dermis. (Hematoxylin-eosin stain;
original magnification: 3100.)
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mediated by either coagulation or fibrinolysis disor-
ders.5-7 Systemic therapeutic recommendations
mainly refer to antiplatelet, antithrombotic, antico-
agulant, and fibrinolytic medications, which are
often unsatisfactory.1,8,9 We believe this is the first
report of successful treatment of recalcitrant cuta-
neous ulcers in a patient with livedoid vasculopathy
by autologous PRP. We propose that autologous PRP
therapy could be an appropriate alternative modality
when the degree of healing with conventional
treatment appears to be unsatisfactory.
PRP consists of a high concentration of platelets
that promotewoundhealing throughchemotaxis, cell
proliferation, angiogenesis, and tissue remodeling.Platelets are critically important in thewound-healing
process. They translocate rapidly to the wound site
and adhere to the damaged tissue, initiating a
healing reaction that includes the release of various
cytokines and growth factors. Topical application of
PRP to acute and chronic skin ulcers significantly
accelerated the epithelization process, likely through
up-regulation of the cell cycle regulatory proteins
cyclin A and CDK4.10 We propose that these mecha-
nisms could accelerate the healing of recalcitrant
cutaneous ulcers in livedoid vasculopathy.
Additional randomized, controlled clinical trials are
required to adequately address the localized treat-
ment effects.
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